{"id":28254,"date":"2022-07-07T22:38:00","date_gmt":"2022-07-07T14:38:00","guid":{"rendered":"https:\/\/flcube.com\/?p=28254"},"modified":"2025-02-27T22:43:53","modified_gmt":"2025-02-27T14:43:53","slug":"beigene-and-innorna-partner-on-mrna-lnp-therapeutic-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=28254","title":{"rendered":"BeiGene and InnoRNA Partner on mRNA-LNP Therapeutic Development"},"content":{"rendered":"\n

China-based biotech firm BeiGene (HKG: 6160<\/a>, SHA: 688235<\/a>, NASDAQ: BGNE) announced a strategic partnership with compatriot company InnoRNA, a specialist in lipid-nanoparticle (LNP)-based delivery technology and mRNA drug discovery. The collaboration aims to leverage InnoRNA\u2019s innovative platform for developing mRNA-based therapeutics.<\/p>\n\n\n\n

Agreement Terms<\/strong>
Under the deal, InnoRNA will receive an upfront cash payment and is eligible for additional milestone-based payments tied to development, regulatory, and commercial achievements, plus tiered royalties for mRNA-LNP research programs. BeiGene gains exclusive global rights to commercialize therapies co-developed by the two firms. InnoRNA also receives an upfront payment and further milestones for granting BeiGene non-exclusive access to its proprietary LNP platform.<\/p>\n\n\n\n

Company Profiles<\/strong>
BeiGene, a global biopharma player, focuses on cancer-related drug development. InnoRNA\u2019s expertise lies in mRNA drug discovery and LNP delivery systems, which are critical for stabilizing mRNA molecules and enabling targeted delivery. The partnership combines BeiGene\u2019s clinical and commercial capabilities with InnoRNA\u2019s technological strengths.<\/p>\n\n\n\n

Market Implications<\/strong>
The mRNA-LNP field has gained traction post-COVID-19 vaccine success. This alliance positions BeiGene to tap into mRNA therapies, a promising area for treating genetic and infectious diseases. InnoRNA\u2019s platform could accelerate drug development timelines and enhance therapeutic efficacy.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based biotech firm BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) announced a strategic partnership with…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2092,847,63,846,848],"class_list":["post-28254","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-beone-medicines","tag-hkg-6160","tag-mrna","tag-nasdaq-bgne","tag-sha-688235"],"yoast_head":"\nBeiGene and InnoRNA Partner on mRNA-LNP Therapeutic Development - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based biotech firm BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) announced a strategic partnership with compatriot company InnoRNA, a specialist in lipid-nanoparticle (LNP)-based delivery technology and mRNA drug discovery. The collaboration aims to leverage InnoRNA\u2019s innovative platform for developing mRNA-based therapeutics.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=28254\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeiGene and InnoRNA Partner on mRNA-LNP Therapeutic Development\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=28254\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-07T14:38:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-27T14:43:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28254#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28254\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BeiGene and InnoRNA Partner on mRNA-LNP Therapeutic Development\",\"datePublished\":\"2022-07-07T14:38:00+00:00\",\"dateModified\":\"2025-02-27T14:43:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28254\"},\"wordCount\":208,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"BeOne Medicines\",\"HKG: 6160\",\"mRNA\",\"NASDAQ: BGNE\",\"SHA: 688235\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=28254#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28254\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=28254\",\"name\":\"BeiGene and InnoRNA Partner on mRNA-LNP Therapeutic Development - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-07-07T14:38:00+00:00\",\"dateModified\":\"2025-02-27T14:43:53+00:00\",\"description\":\"China-based biotech firm BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) announced a strategic partnership with compatriot company InnoRNA, a specialist in lipid-nanoparticle (LNP)-based delivery technology and mRNA drug discovery. The collaboration aims to leverage InnoRNA\u2019s innovative platform for developing mRNA-based therapeutics.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28254#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=28254\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28254#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeiGene and InnoRNA Partner on mRNA-LNP Therapeutic Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BeiGene and InnoRNA Partner on mRNA-LNP Therapeutic Development - Insight, China's Pharmaceutical Industry","description":"China-based biotech firm BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) announced a strategic partnership with compatriot company InnoRNA, a specialist in lipid-nanoparticle (LNP)-based delivery technology and mRNA drug discovery. The collaboration aims to leverage InnoRNA\u2019s innovative platform for developing mRNA-based therapeutics.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=28254","og_locale":"en_US","og_type":"article","og_title":"BeiGene and InnoRNA Partner on mRNA-LNP Therapeutic Development","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=28254","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-07-07T14:38:00+00:00","article_modified_time":"2025-02-27T14:43:53+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=28254#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=28254"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BeiGene and InnoRNA Partner on mRNA-LNP Therapeutic Development","datePublished":"2022-07-07T14:38:00+00:00","dateModified":"2025-02-27T14:43:53+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=28254"},"wordCount":208,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["BeOne Medicines","HKG: 6160","mRNA","NASDAQ: BGNE","SHA: 688235"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=28254#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=28254","url":"https:\/\/flcube.com\/?p=28254","name":"BeiGene and InnoRNA Partner on mRNA-LNP Therapeutic Development - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-07-07T14:38:00+00:00","dateModified":"2025-02-27T14:43:53+00:00","description":"China-based biotech firm BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) announced a strategic partnership with compatriot company InnoRNA, a specialist in lipid-nanoparticle (LNP)-based delivery technology and mRNA drug discovery. The collaboration aims to leverage InnoRNA\u2019s innovative platform for developing mRNA-based therapeutics.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=28254#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=28254"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=28254#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BeiGene and InnoRNA Partner on mRNA-LNP Therapeutic Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/28254","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=28254"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/28254\/revisions"}],"predecessor-version":[{"id":28255,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/28254\/revisions\/28255"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=28254"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=28254"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=28254"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}